in the absence of a submission from the holder of the marketing authorisation:
atezolizumab (Tecentriq®) is not recommended for use within NHSScotland.
Indication under review: In combination with nab-paclitaxel and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.
Download detailed advice357KB (PDF)
Medicine details
- Medicine name:
- atezolizumab (Tecentriq)
- SMC ID:
- SMC2254
- Indication:
In combination with nab-paclitaxel and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC.
- Pharmaceutical company
- Roche
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 09 December 2019